Assaying the efficacy of dual-antiplatelet therapy: use of a controlled-shear-rate microfluidic device with a well-defined collagen surface to track dynamic platelet adhesion
- 582 Downloads
We report the development and demonstration of an assay that distinguishes the pharmacological effects of two widely used antiplatelet therapies, aspirin (COX-1 inhibitor) and clopidogrel (P2Y12 inhibitor). Whole blood is perfused through a low-volume microfluidic device in contact with a well-characterized (ellipsometry, atomic force microscopy) acid-soluble type I collagen surface. Whole human blood treated in vitro with a P2Y12 inhibitor 2-methylthioadenosine 5′-monophosphate triethylammonium salt (2-MeSAMP) extended the time to the start of platelet recruitment, i.e., platelet binding to the collagen surface. Treatment with 2-MeSAMP also slowed the rate of aggregate buildup, with an overall reduced average platelet aggregate area after 8 min of constant blood flow. A far smaller effect was observed for in vitro treatment with aspirin, for which the rate of change of surface coverage is indistinguishable from controls. In whole blood obtained from patients under treatment with dual-antiplatelet therapy (aspirin and clopidogrel), a significant extension of time to platelet recruitment was observed along with a slowed rate of aggregate buildup and an average aggregate size approximately half that of control measurements. Differentiation of the pharmacological effects of these two well-targeted antiplatelet pathways suggests a role for this assay in determining the antiplatelet effects of these and related new therapeutics in clinical settings.
The authors gratefully acknowledge the help of Ms. Gail Plunkett who assisted with patient recruitment. This material is based upon research supported by Science Foundation Ireland under grant no. 05/CE3/B754.
Disclosure and conflict of interests
The authors declare no conflicts of interest.
- 9.Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621CrossRefGoogle Scholar
- 13.Kent NJ, Basabe-Desmonts L, Meade G, MacCraith BD, Corcoran BG, Kenny D, Ricco AJ (2010) Microfluidic device to study arterial shear-mediated platelet-surface interactions in whole blood: reduced sample volumes and well-characterised protein surfaces. Biomed Microdevices 12:987–1000CrossRefGoogle Scholar
- 15.O’Brien S, Kent N, Lucitt M, Ricco AJ, McAtamney C, Kenny D, Meade G (2012) Effective hydrodynamic shaping of sample streams in a microfluidic parallel-plate flow-assay device: matching whole blood dynamic viscosity. IEEE Trans Biomed Eng 59:374–382Google Scholar
- 20.Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image processing with ImageJ. Biophoton Int 11:36–42Google Scholar
- 31.Roald HE, Barstad RM, Kierulf P, Skjørten F, Dickinson JP, Kieffer G, Sakariassen KS (1994) Clopidogrel—a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 71:655–662Google Scholar
- 32.Barstad RM, Orvim U, Hamers MJ, Tjonnfjord GE, Brosstad FR, Sakariassen KS (1996) Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 75:827–832Google Scholar
- 33.Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I (2007) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 98:1316–1322Google Scholar